


# How Shall We Analyze Change From Baseline in COA Endpoints? Is MMRM Bowing Out?

ISPOR Europe 2022

7 November 2022

Virtual




# Introduction

This panel will discuss the suitability of Mixed Model Repeated Measures (MMRM) to evaluate change from baseline in COA data

COA data typically collected at multiple timepoints during a clinical trial

Often, MMRM is considered to analyze COA data for change from baseline endpoints




# Introduction

MMRM limitations must be considered alongside research objectives and context of use

- Assumes missing at random
- Consider intercurrent events, e.g., treatment discontinuation or death

Speakers will discuss considerations for evaluating whether MMRM is an appropriate method to use, including threats to interpretability of the data, and when not appropriate, what alternative methods might be considered



# Speakers

## Ashley F. Slagle, PhD

- Moderator
- COA / Endpoint Scientific and Regulatory Advisor
- Aspen Consulting, LLC

## Andrew Potter, PhD

- Speaker/Panelist
- Senior Mathematical Statistician
- Office of Biostatistics, FDA-CDER

## James Bell, PhD

- Speaker/Panelist
- Biostatistician and Pharmaceutical Scientist
- Elderbrook Solutions GmbH

## Konstantina Skaltsa, PhD

- Speaker/Panelist
- Director, Statistics
- Patient Centered Solutions, IQVIA



# Panel Discussion

